STING1 and cancer: Notably, the cyclic GMP‐AMP synthase (cGAS)‐stimulator of interferon genes (STING) signaling pathway has emerged as a promising target for cancer immunotherapy.[2, 3] The accumulation of tumor‐derived double‐stranded DNA (dsDNA) in the cytoplasm triggers the cGAS sensor to produce cyclic GMP‐AMP (cGAMP), which in turn activates the STING protein.[4, 5] Following this, STING stimulates the transcription of genes involved in the innate immune response, resulting in the synthesis of type I interferons (IFN‐I), which activate a robust antitumor immune response.[6, 7]